Thoracic Research and Practice
Original Article

The Effects of Smoking Properties and Demographic Properties on the Results of Smoking Cessation Therapy

1.

Gazi Osman Paşa Üniversitesi Tıp Fakültesi, Göğüs Hastalıkları ve Tüberküloz Anabilim Dalı, Tokat, Türkiye

2.

Dokuz Eylül Üniversitesi Tıp Fakültesi, Göğüs Hastalıkları Anabilim Dalı, İzmir, Türkiye

3.

Dokuz Eylül Üniversitesi Tıp Fakültesi, Halk Sağlığı Anabilim Dalı, İzmir, Türkiye

4.

Adnan Menderes Üniversitesi Tıp Fakültesi, Göğüs Hastalıkları ve Tüberküloz Anabilim Dalı, Aydın, Türkiye

Thorac Res Pract 2007; 8: Toraks Dergisi 110-114
Read: 1493 Downloads: 1019 Published: 18 July 2019

Abstract

We aimed to evaluate the effects of demographics and therapy modalities on the outcome of smoking cessation therapies in our clinic. 230 people filled a questionnaire via telephones interview. 68 persons who quitted smoking were defined as controls, and 101 subjects who couldn’t quit were defined as the case group. There was no significant difference between case and control groups for age, gender and education. Presence of systemic and pulmonary disease did not affect quitting. Being married decreases the risk of not quitting by 0.4 times. At 6th month, 48.6% of those using bupropion, 35.9% of those using nicotine replacement therapy (NRT), 44,4% of those using combination therapy, and 17.6% of those having undergone only education program quitted. Eight of the bupropion, 18 of the NRT, 2 of the combination therapy, and 2 of the only education groups were not smoking at the end of the first year. The period of therapy was 4.71±6.43 weeks in case group and 6.64±3.14 weeks in control group. The difference was significiant. 55.6% of the cases and 86.2% of the controls had sufficient therapy (≥4 weeks) periods. It’s shown that sufficient duration of therapy decreases the risk of not quitting about 0.2 times (OR 0.2, 95% CI 01-0.5, p=0.000). It was determined that the mean duration of restarting smoking was 2.4±1.9 months at the first attemp to stop smoking. Quitting rate can be increased by using therapies at least four weeks, and additional controls after six months are necessary to prevent recurrences.

Files
EISSN 2979-9139